NDC 80425-0018-01 - Cyclobenzaprine HCL
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 80425-0018
- Requested NDC
- 80425-0018-01
- Package NDCs from labels
- 80425-0018-2, 80425-0018-3, 80425-0018-1, 80425-0018-01
- Manufacturer
- Advanced Rx of Tennessee, LLC
- Effective date
- 2024-12-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cyclobenzaprine HCL - Advanced Rx of Tennessee, LLC | Advanced Rx of Tennessee, LLC | 2024-12-31 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 80425-0018-1 | Cyclobenzaprine HCL | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 8 | |
| 80425-0018-2 | Cyclobenzaprine HCL | 60 in 1 BOTTLE | TABLET, FILM COATED | 60 | 8 | |
| 80425-0018-3 | Cyclobenzaprine HCL | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 8 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 80425-0018 | CYCLOBENZAPRINE HCL TABLET, FILM COATED [ADVANCED RX OF TENNESSEE, LLC] | 8 | Current NDC, Legacy NDC, 3 package rows | 20250101_afcab35f-4ab9-33a4-e053-2a95a90ad529.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 80425-0018-1 | EA - Each | 80425-0018 | 4b64f1c0-c241-4839-b0e1-a721173296d8 | 1 | 2023-03-13 |
| 80425-0018-2 | EA - Each | 80425-0018 | 0b1b8bdf-7a8d-4901-b71b-da92a9ceb5d0 | 1 | 2023-03-13 |
| 80425-0018-3 | EA - Each | 80425-0018 | 71405b22-828e-47c4-939a-69cdf17fde83 | 1 | 2023-03-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cyclobenzaprine HCL ER | CYCLOBENZAPRINE HCL ER | Direct_Rx | e4a3383a-7b30-25b7-e053-2995a90a341b | 2025-01-22 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine HCL ER | CYCLOBENZAPRINE HCL ER | Direct_Rx | ed0b9acc-132f-64c0-e053-2995a90a198c | 2025-01-22 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | DirectRx | ceb56ab8-4a76-6dee-e053-2995a90aab30 | 2025-01-20 | Warnings, Adverse reactions | ANDA208170 828320 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | DIRECT RX | a58cf759-048b-6740-e053-2a95a90a8b43 | 2025-01-17 | Warnings, Adverse reactions | ANDA208170 828348 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | DIRECT RX | a512d34c-8164-0c04-e053-2995a90a1942 | 2025-01-17 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | 01e18825-1cf9-a98c-e063-6294a90ae0a4 | 2025-01-14 | Warnings, Adverse reactions | ANDA208170 828320 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 3dd2bde1-f06d-493a-91c7-22b28a5e1699 | 2025-01-07 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE | EXELAN PHARMACEUTICALS, INC. | cf81da00-7c6d-4477-bb70-b3c2abea177a | 2025-01-01 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine HCL | CYCLOBENZAPRINE HCL | Advanced Rx of Tennessee, LLC | afca2a49-6424-7b6a-e053-2a95a90ad41e | 2024-12-31 | Warnings, Adverse reactions | 828320 0VE05JYS2P |
| Cyclobenzaprine HCL | CYCLOBENZAPRINE HCL | Advanced Rx of Tennessee, LLC | afca1267-4d8f-7453-e053-2995a90a865c | 2024-12-31 | Warnings, Adverse reactions | ANDA208170 828320 0VE05JYS2P |
| Cyclobenzaprine HCL | CYCLOBENZAPRINE HCL | Advanced Rx of Tennessee, LLC | afcab35f-4ab9-33a4-e053-2a95a90ad529 | 2024-12-31 | Warnings, Adverse reactions | ANDA208170 80425-0018-3 80425-0018-2 80425-0018-1 80425-0018 80425001801 828348 2a985a04-15cf-b8b6-e063-6394a90a4231 afcab35f-4ab9-33a4-e053-2a95a90ad529 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Advanced Rx of Tennessee, LLC | afcad582-ab59-4f70-e053-2a95a90a04e4 | 2024-12-31 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine HCL | CYCLOBENZAPRINE HCL | Advanced Rx of Tennessee, LLC | b062cb80-79a9-c5d8-e053-2a95a90aecfc | 2024-12-31 | Warnings, Adverse reactions | 828299 0VE05JYS2P |
| Cyclobenzaprine HCL | CYCLOBENZAPRINE HCL | Advanced Rx Pharmacy of Tennessee, LLC | c859f63a-09de-4eec-e053-2a95a90a312f | 2024-12-31 | Warnings, Adverse reactions | 828320 0VE05JYS2P |
| Cyclobenzaprine HCL ER | CYCLOBENZAPRINE HCL | Advanced Rx Pharmacy of Tennessee, LLC | f8360da5-f1d3-1d89-e053-6294a90ad31c | 2024-12-31 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | db49801d-9bde-5dd0-e053-2a95a90aee53 | 2024-12-26 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Advanced Rx of Tennessee, LLC | 2998c9e6-2f60-ef35-e063-6394a90a7bc7 | 2024-12-18 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Quality Care Products LLC | 794d350b-6c88-41d5-b68b-3e2c57ee2a4f | 2024-12-17 | Warnings, Adverse reactions | 828299 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | American Health Packaging | 5f321a03-ccfb-4c11-ac60-a461a5580c69 | 2024-12-13 | Warnings, Adverse reactions | 828320 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Bryant Ranch Prepack | 4c51f56b-33c3-4611-bba8-876d9dde7aff | 2024-11-27 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.